SERS-based dynamic monitoring of minimal residual disease markers with high sensitivity for clinical applications

Nanoscale ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 2460-2467 ◽  
Author(s):  
Yujie Wang ◽  
Shenfei Zong ◽  
Na Li ◽  
Zhuyuan Wang ◽  
Baoan Chen ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
High Sensitivity ◽  
Clinical Applications ◽  
Dynamic Monitoring ◽  
Disease Markers ◽  
Minimal Residual

We report an SERS-based method for dynamic monitoring of minimal residual disease markers with high sensitivity for clinical applications.

Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 3522-3522 ◽  
Author(s):  
Michael J. Overman ◽  
Jean-Nicolas Vauthey ◽  
Thomas A. Aloia ◽  
Claudius Conrad ◽  
Yun Shin Chun ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
Tumor Resection ◽  
High Sensitivity ◽  
Disease Recurrence ◽  
Circulating Tumor Dna ◽  
High Rate ◽  
Curative Intent ◽  
Minimal Residual

3522 Background: Preliminary data suggests that ctDNA can serve as a marker of minimal residual disease following colorectal cancer (CRC) tumor resection. Applicability of current ctDNA testing is limited by the requirement of sequencing known individual tumor mutations. We explored the applicability of a multi-gene panel ctDNA detection technology in CRC. Methods: Plasma was prospectively collected from CRC patients (pts) undergoing hepatic resections with curative intent between 1/2013 to 9/2016. In a blinded manner 5ml of preoperative (preop) and immediate post-operative (postop) plasma were tested using a novel 30kb ctDNA digital sequencing panel (Guardant Health) covering SNVs in 21 genes and indels in 9 genes based on the landscape of genomic alterations in ctDNA from over 10,000 advanced cancer pts with a high theoretical sensitivity (96%) for CRC. Median unique molecule coverage for this study is 9000 for cfDNA inputs ranging from 10 – 150 ng (media input preop = 27 ng, median input postop = 49 ng) with 120,000X sequencing depth on an IIlumina HiSeq2500. Results: A total of 54 pts underwent liver metastectomies with curative intent with a median follow-up of 33 months. Preop blood was a median of 49 days from last systemic chemotherapy and 3 days prior to surgery; postop blood was a median of 17 days after resection. Tumor mutations from standard of care hotspot multigene panel testing (at MDACC) were identified in 46 of 54 pts (85%). Preop ctDNA mutation detection rate was 80% (43/54) and 44% (24/54) in postop setting, with postop median allele frequency of 0.16% (range 0.01% to 20%). In pts with a minimum of 1 year follow up, sensitivity of postop ctDNA for residual disease was 58% (95%CI; 41%-74%), and specificity was 100% (66%-100%). In 43 patients who underwent successful resection of all visible disease, postop detection of ctDNA significantly correlated with RFS (P = 0.002, HR 3.1; 95% CI 1.7-9.1) with 2-year RFS of 0% vs. 47%. Recurrence was detected in ctDNA a median of 5.1 months prior to radiographic recurrence. Conclusions: The detection of postop ctDNA using an NGS panel-based approach is feasible and is associated with a very high rate of disease recurrence.

scholarly journals Whole-Genome Sequencing Identifies Patient-Specific DNA Minimal Residual Disease Markers in Neuroblastoma

2015 ◽  
Vol 17 (1) ◽  
pp. 43-52 ◽  
Author(s):  
Esther M. van Wezel ◽  
Danny Zwijnenburg ◽  
Lily Zappeij-Kannegieter ◽  
Erik Bus ◽  
Max M. van Noesel ◽  
...  
Keyword(s):  
Whole Genome Sequencing ◽  
Minimal Residual Disease ◽  
Genome Sequencing ◽  
Residual Disease ◽  
Patient Specific ◽  
Whole Genome ◽  
Disease Markers ◽  
Minimal Residual

scholarly journals Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients

2015 ◽  
Vol 10 (5) ◽  
pp. 3228-3232 ◽  
Author(s):  
NOBUYUKI YAMAMOTO ◽  
AIKO KOZAKI ◽  
TRI BUDI HARTOMO ◽  
TOMOKO YANAI ◽  
DAIICHIRO HASEGAWA ◽  
...  
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Differential Expression ◽  
Minimal Residual Disease ◽  
Peripheral Blood ◽  
Residual Disease ◽  
Disease Markers ◽  
Minimal Residual

Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid Leukemia

Chemotherapy ◽  
2020 ◽  
pp. 1-5
Author(s):  
Orhan Kemal Yucel ◽  
Mustafa Serkan Alemdar ◽  
Unal Atas ◽  
Levent Undar
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
High Sensitivity ◽  
Core Binding Factor ◽  
Hematopoietic Stem ◽  
Real Time Quantitative Pcr ◽  
End Of Treatment ◽  
Binding Factor ◽  
Minimal Residual

Although core-binding factor AML (CBF-AML) has a favorable outcome, disease relapses occur in up to 35% of patients. Minimal residual disease (MRD) monitoring is one of the important tools to enable us to identify patients at high risk of relapse. Real-time quantitative PCR allows MRD to be measured with high sensitivity in CBF-AML. If the patient with CBF-AML is in complete morphologic remission but MRD positive at the end of treatment, what to do for those is still uncertain. Preemptive intervention approaches such as allogeneic hematopoietic stem cell transplantation or intensive chemotherapy could be an option or another strategy might be just follow-up until overt relapse developed. Although using hypomethylating agents as a maintenance therapy has not been widely explored, here, we report a case with CBF-AML who was still positive for MRD after induction/consolidation therapies and whose MRD was eradicated by azacitidine maintenance.

Rearranged immunoglobulin light chain genes as minimal residual disease markers in intermediate- and high-grade malignant B cell non-Hodgkin’s lymphoma

Leukemia ◽  
1998 ◽  
Vol 12 (11) ◽  
pp. 1810-1816 ◽  
Author(s):  
M Hoogeveen-Westerveld ◽  
PE Hupkes ◽  
D Doekharan ◽  
LCJ Dorssers ◽  
MB van’t Veer ◽  
...  
Keyword(s):  
B Cell ◽  
Minimal Residual Disease ◽  
Light Chain ◽  
Residual Disease ◽  
Hodgkin's Lymphoma ◽  
High Grade ◽  
Immunoglobulin Light Chain ◽  
Disease Markers ◽  
Non Hodgkin's Lymphoma ◽  
Minimal Residual

SOX11, CCND1, BCL1/IgH and IgH-VDJ: a battle of minimal residual disease markers in mantle cell lymphoma?

2015 ◽  
Vol 56 (9) ◽  
pp. 2724-2727 ◽  
Author(s):  
Anita T. Simonsen ◽  
Marie Schou ◽  
Camilla D. Sørensen ◽  
Hans H. N. Bentzen ◽  
Charlotte G. Nyvold
Keyword(s):  
Mantle Cell Lymphoma ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Cell Lymphoma ◽  
Disease Markers ◽  
Mantle Cell ◽  
Minimal Residual

scholarly journals The Role and Impact of Minimal Residual Disease in NSCLC

2021 ◽  
Vol 23 (12) ◽  
Author(s):  
Daniele Frisone ◽  
Alex Friedlaender ◽  
Alfredo Addeo
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
High Sensitivity ◽  
Current Evidence ◽  
Strong Correlations ◽  
Future Trial ◽  
Liquid Biopsies ◽  
Curative Intent ◽  
Risk Of Disease ◽  
Minimal Residual

Abstract Purpose of Review There has been a huge development in the assessment of malignancies through liquid biopsies last years, especially for NSCLC, where its use has become part of clinical practice in some settings. We aim to summarize current evidence about minimal residual disease and its use in lung cancer. Recent Findings Recent studies using ctDNA in NSCLC but also in other types of cancer found strong correlations between the presence of ctDNA and the risk of disease progression or death after curative intent, despite current technical difficulties in performing this analysis (high sensitivity and specificity required). Summary Evaluation of MRD in NSCLC, especially through ctDNA, could be an important point in future trial designs and could permit a more “targeted” adjuvant treatment.

Sign in / Sign up

Export Citation Format

Share Document